Cis-dischlorodiammine-platinum class drug side effect inhibition or treatment target

• Main Authors: JING XU, WANG DAOQING, BAO ZHIGUO, ZHENG HUIYAN, WANG YAJUN, WU JING
• Format: Patent
• Language: Chinese; English
• Published: 10.01.2020
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention belongs to the technical field of side effect inhibition of cancer drug treatment, and relates to a cis-dischlorodiammine-platinum class drug side effect inhibition or treatment target.According to the cis-dischlorodiammine-platinum class drug side effect inhibition or treatment target, aiming at the problem of kidney injury in the course of cancer treatment, an LncRNA matrilineal expression gene 3 is provided as a treatment target of the kidney injury, the inhibitory effect of paeonol on the LncRNA matriarchal expression gene 3 is further provided, and a novel idea is providedfor side effect inhibition in the course of cancer treatment. 本发明属于癌症药物治疗副作用抑制技术领域，涉及一种顺铂类药物副作用抑制或治疗靶点。本发明针对癌症治疗过程中存在的肾脏损伤问题，提出LncRNA母系表达基因3作为其治疗靶点，并提出丹皮酚对LncRNA母系表达基因3的抑制效果，为癌症治疗过程中副作用抑制提供了新思路。